Gantenerumab - Roche
Alternative Names: R-1450; RG-1450; RO-4909832Latest Information Update: 01 Oct 2024
Price :
$50 *
At a glance
- Originator MorphoSys
- Developer Chugai Pharmaceutical; Roche; Washington University School of Medicine
- Class Antidementias; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 28 Jul 2024 Efficacy data from a phase II/III trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
- 28 Jul 2024 Adverse event data from a phase II/III DIAN-TU trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
- 28 Jul 2024 Efficacy data from a phase II/III DIAN-TU trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)